The latest lymphoma news
Potential cause of immunotherapy-related neurotoxicity
New research has uncovered the previously unknown presence of CD19 — a B cell molecule…
Browsing: Lymphoma
The behaviour of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies…
Excellent research results for CAR-T Cell therapy against Hodgkin lymphoma
CAR-T cell therapy, which attacks cancer cells using a person’s reprogrammed immune cells, has been…
Engineered immune cells recognise, attack human and mouse solid-tumour cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and…
FDA grants accelerated approval to tazemetostat for follicular lymphoma
The Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for…
FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma
The Food and Drug Administration (FDA) granted accelerated approval to selinexor for adult patients with…
Early clinical trial supports tumour cell-based vaccine for mantle cell lymphoma
A phase I/II clinical trial by researchers at Stanford University, USA, suggests that vaccines prepared…
EHA 2020: A new treatment paradigm in relapsed refractory Hodgkin lymphoma
Patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) have few treatment options when they are…
EHA 2020: PET-guided therapy allows omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma
For decades, combined modality treatment (CMT) comprising of four cycles of chemotherapy and radiotherapy has…
Phase III results show rituximab excels against paediatric Burkitt lymphoma
Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported in the New England Journal of…